Tear test: new study probes how dry eye drug alters eye proteins
NCT ID NCT07490535
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will measure changes in tear fluid proteins in 36 adults with dry eye disease who are already using lifitegrast (Xiidra) eye drops. Researchers want to see how the drug affects these biomarkers over 84 days. The goal is to better understand dry eye and how the treatment works, not to test a new cure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DRY EYE SYNDROME (DES) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pittsburgh Research Institute
Sewickley, Pennsylvania, 15143, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Fewer drops, same relief? trial tests Twice-Daily systane complete against standard Four-Times-Daily regimen
- Premature birth may leave lasting marks on the optic nerve
- Can a simple eye drop stop dry eye after LASIK?
- Eye rinse device aims to soothe dry eye pain
- Scientists hunt for protein clues in severe dry eye treatment
- Massive eye database aims to unlock secrets of blinding diseases